Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript
Source: SeekingAlpha
2025-10-24 17:37:40 ET
Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma October 24, 2025 1:30 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript
Xencor Inc.
NASDAQ: XNCR
XNCR Trading
-3.21% G/L:
$11.775 Last:
239,081 Volume:
$11.82 Open:
XNCR Latest News
XNCR Stock Data
$902,628,328
68,011,331
N/A
68
N/A
Biotechnology & Life Sciences
Healthcare
US
Pasadena
